ARCT
Arcturus Therapeutics Holdings Inc.
26.55
+
0.38
1.45%
2 x 26.46
2 x 26.58
bid
ask
2 @ 04:00 PM
26.55+0.00 (0.00%)
Bearish
16
Bullish
27
sentiment
25.84
day range
26.86
17.71
52 week range
42.99
Prev Close26.17
Open26.28
Low25.84
High26.86
Volume259.93K
Avg. Volume484.68K
Market Cap714.60M
Inst. Own90.42%
Beta2.60
Short Ratio8.30
Div & Yield0.00 /
EPS-1.12
P/E0.00
1yr Target67.63
50day MA34.06
200day MA29.94
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript | seekingalpha.com • |
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates | zacks.com • |
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why | zacks.com • |
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff | investorplace.com • |
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 | investorplace.com • |
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition | investorplace.com • |
Profile
...
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-08 | 2024-03 | -1.17 | N/A | N/A | N/A |
2024-03-07 | 2023-12 | -1.69 | -0.32 | 1.37 | 81.07% |
2023-11-14 | 2023-09 | -1.79 | -0.61 | 1.18 | 65.92% |
2023-08-07 | 2023-06 | 0.09 | -1.98 | -2.07 | -2300.00% |
2023-05-09 | 2023-03 | 2.92 | 0.88 | -2.04 | -69.86% |
2023-03-28 | 2022-12 | -1.86 | 4.33 | 6.19 | 332.80% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-21 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-24 | CHIVUKULA PADMANABH | Chief Operating Officer | 473.45K | Sale |
2019-08-19 | FARRELL PETER CRAIG | Director | 0.00 | Purchase |
2023-07-13 | KUMMERFELD KEITH C | Officer | 950.00 | Sale |
2022-12-14 | MARQUET MAGDA | Director | 0.00 | Purchase |
2022-11-22 | PAYNE JOSEPH E | Chief Executive Officer | 1.48M | Purchase |
2023-08-14 | SASSINE ANDY H | Chief Financial Officer | 270.53K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Federated Hermes, Inc. | 4.78M | 137.05M | 17.97% |
2023-06-29 | Blackrock Inc. | 1.99M | 57.14M | 7.49% |
2023-06-29 | State Street Corporation | 1.98M | 56.91M | 7.46% |
2023-09-29 | ARK Investment Management, LLC | 1.90M | 48.58M | 7.15% |
2023-06-29 | Vanguard Group Inc | 1.63M | 46.70M | 6.12% |
2023-06-29 | Nikko Asset Management Americas, Inc. | 1.40M | 40.29M | 5.28% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-07-30 | Federated Hermes Kaufmann Fund | 2.48M | 86.53M | 9.31% |
2023-07-30 | Federated Hermes Kaufmann Small Cap Fund | 2.23M | 77.96M | 8.38% |
2023-09-29 | ARK ETF Tr-ARK Genomic Revolution ETF | 1.89M | 48.17M | 7.09% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.34M | 40.54M | 5.02% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 904.63K | 27.46M | 3.40% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 716.97K | 20.56M | 2.70% |
Dividend
...
Dividend | Date |
---|---|
0.0085 | 2013-01-08 |
0.0085 | 2013-01-04 |
0.0086 | 2012-12-05 |
0.0086 | 2012-11-06 |
0.0086 | 2012-10-03 |
0.0086 | 2012-09-05 |
Split
...
Split | Date |
---|---|
1 : 7 | 2017-11-16 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
-
-
Don’t try to regain all your losses back from yesterday’s blow out. Get your profit while you still can!
-
-
$ARCT.. glad I sold yesterday! The lackluster market is caused this to go down. I will wait a day or two and get back in.
-
-
$ARCT.. coming right back down
-
$ARCT... all is good for now.. if market starts to go down this will tank pretty good!
-
$ARCT.. it’s the market.. relax!
-
$ARCT.. going to be a great week!
-
-
$ARCT... easy call here. Doesn’t make sense selling. Buy more.. this is easy money.
-
$ARTC.. going north.. no doubts here!!
-
$ARCT.. it’s the market lol.. relax it will pop back.. buy more
-
$ARCT.. easy hold! It will go back up!
-
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
investorplace.com • -
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
investorplace.com • -
Arcturus: H1 2024 Rare Disease Drug Data On Deck
seekingalpha.com • -
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
investorplace.com • -
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
investorplace.com • -
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
investorplace.com • -
Arcturus: Interim Readout Of Rare Disease Data In Coming Months
seekingalpha.com • -
Arcturus Therapeutics to Attend Upcoming Investor Conferences
businesswire.com • -
New Strong Sell Stocks for August 10th
zacks.com • -
3 Biotech Stocks to Buy Before the Breakout
investorplace.com • -
3 Biotech Stocks for Getting Rich in 2023
investorplace.com • -
Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
seekingalpha.com • -
Unlocking Arcturus' Potential And De-Risking Through Partnerships
seekingalpha.com • -
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
Arcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine Delivery
seekingalpha.com • -
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
investorplace.com • -
Arcturus Therapeutics to Attend the Following Investor Conferences
businesswire.com • -
7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later
investorplace.com • -
Arcturus: Potential Based On Rare Disease Therapy ARCT-810
seekingalpha.com • -
Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
seekingalpha.com • -
Arcturus Therapeutics Presents Specific Asian COVID-19 Opportunity
seekingalpha.com • -
7 Busted Biotech Stocks Due for a Rebound
investorplace.com • -
Arcturus Therapeutics: Q1 Earnings Insights
benzinga.com • -
Arcturus Therapeutics to Present at Upcoming Investor Conferences
businesswire.com • -
Is Arcturus Therapeutics a Buy?
fool.com • -
Why Teladoc Health, Arcturus And Meridian Are Moving Today
benzinga.com •